Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Pain drug developer Latigo Biotherapeutics has joined a queue of more than half a dozen other biotechnology startups that announced this month plans to go public. Founded in 2018 by the venture ...

Eli Lilly plans to acquire psychedelics specialist AtaiBeckley through a multibillion-dollar deal that shows big pharma’s growing endorsement of a once-dimissed, now rapidly emerging research field.

BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and ...

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum ...

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech ...